Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with placebo (very low certainty).
Leaving the study early · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
CHLORPROMAZINE may leads to lower leaving the study early compared with PLACEBO (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
1 finding from 1 review
Leaving the study early · adults with schizophrenia
It is very uncertain whether ASENAPINE changes leaving the study early ‐ any reason compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
It is very uncertain whether ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes leaving the study early/ loss to compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).
1 finding from 1 review